Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

被引：0
|
作者：
Vedder, A. C.
Linthorst, G. E.
Houge, G.
Groener, J. E. M.
Ormel, E. E.
Bouma, B. J.
Aerts, J. M. F. G.
Hirth, A.
Hollak, C. E. M.
机构：
[1] AMC, Dept Intern Med Endocr Metab, Amsterdam, Netherlands
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] AMC, Dept Biochem Med, Amsterdam, Netherlands
[4] AMC, Dept Cardiol, Amsterdam, Netherlands
[5] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2007年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [21] Agalsidase Alfa and Agalsidase beta Have Similar Effects on Outcomes in Fabry disease- results from the canadian Fabry disease initiative
    West, Michael
    Bichet, Daniel
    Casey, Robin
    Clarke, Joe
    Sirrs, Sandra
    LeMoine, Kaye
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (02) : S46 - S46
  • [22] Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa
    Ramaswami, Uma
    ACTA PAEDIATRICA, 2008, 97 : 38 - 40
  • [23] Agalsidase alfa (Replagal (TM)) in the treatment of Anderson-Fabry disease
    Pastores, Gregory M.
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (03): : 291 - 300
  • [24] The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease
    Morell, Chantal F.
    Clarke, Joe T. R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (05) : 631 - 639
  • [25] Treatment with agalsidase beta during pregnancy in Fabry disease
    Politei, Juan M.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (02) : 428 - 429
  • [26] MINIMAL ANTI-DRUG ANTIBODY FINDINGS OF AGALSIDASE ALFA FOR FABRY DISEASE: TREATMENT-NAOVE OR FORMERLY TREATED WITH AGALSIDASE BETA
    Goker-Alpan, O.
    Nedd, K.
    Shankar, S.
    Lien, Y. H.
    Barshop, B. A.
    Holida, M.
    Hillman, R.
    Ibrahim, J.
    Mardach, R.
    Weinreb, N.
    Rever, B.
    Forte, R.
    Desai, A.
    Wijatyk, A.
    Chang, P.
    Martin, R.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S148 - S148
  • [27] Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa
    Abcde, Hsiang-Yu Lin
    Huang, Yu-Hsiu
    Liao, Hsuan-Chieh
    Liu, Hao-Chuan
    Hsu, Ting-Rong
    Shen, Chia-I
    Li, Shao-Tzu
    Li, Cheng-Fang
    Lee, Li-Hong
    Lee, Pi-Chang
    Huang, Chun-Kai
    Chiang, Chuan-Chi
    Lin, Shuan-Pei
    Niu, Dau-Ming
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (04) : 190 - 197
  • [28] Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
    Tsuboi, Kazuya
    Yamamoto, Hiroshi
    GENETICS IN MEDICINE, 2012, 14 (09) : 779 - 786
  • [29] Effect of agalsidase alfa on pain in adolescents with fabry disease: Data from fos - The Fabry outcome survey
    Ramaswami, U.
    Pintos, G.
    Kalkum, G.
    Parini, R.
    Beck, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 46 - 46
  • [30] SWITCH FROM AGALSIDASE BETA TO AGALSIDASE ALFA IN THE ENZYME REPLACEMENT THERAPY OF PATIENTS WITH FABRY DISEASE IN LATIN AMERICA
    Ripeau, Diego
    Amartino, Hernan
    Cedrolla, Martin
    Urtiaga, Luis
    Urdaneta, Bella
    Cano, Marilis
    Valdez, Rita
    Antongiovanni, Norberto
    Masllorens, Francisca
    MEDICINA-BUENOS AIRES, 2017, 77 (03) : 173 - 179
12345